Journal Article
. 2013 Oct;141(3).
doi: 10.1007/s10549-013-2699-3.

The molecular diversity of Luminal A breast tumors

Giovanni Ciriello 1 Rileen Sinha  Katherine A Hoadley  Anders S Jacobsen  Boris Reva  Charles M Perou  Chris Sander  Nikolaus Schultz  
Affiliations
  • PMID: 24096568
  •     50 References
  •     42 citations

Abstract

Breast cancer is a collection of diseases with distinct molecular traits, prognosis, and therapeutic options. Luminal A breast cancer is the most heterogeneous, both molecularly and clinically. Using genomic data from over 1,000 Luminal A tumors from multiple studies, we analyzed the copy number and mutational landscape of this tumor subtype. This integrated analysis revealed four major subtypes defined by distinct copy-number and mutation profiles. We identified an atypical Luminal A subtype characterized by high genomic instability, TP53 mutations, and increased Aurora kinase signaling; these genomic alterations lead to a worse clinical prognosis. Aberrations of chromosomes 1, 8, and 16, together with PIK3CA, GATA3, AKT1, and MAP3K1 mutations drive the other subtypes. Finally, an unbiased pathway analysis revealed multiple rare, but mutually exclusive, alterations linked to loss of activity of co-repressor complexes N-Cor and SMRT. These rare alterations were the most prevalent in Luminal A tumors and may predict resistance to endocrine therapy. Our work provides for a further molecular stratification of Luminal A breast tumors, with potential direct clinical implications.

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Emerging targeted agents in metastatic breast cancer.
Dimitrios Zardavas, José Baselga, Martine Piccart.
Nat Rev Clin Oncol, 2013 Mar 06; 10(4). PMID: 23459626
Highly Cited. Review.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Igor Girault, Florence Lerebours, +4 authors, Ivan Bièche.
Clin Cancer Res, 2003 Apr 10; 9(4). PMID: 12684393
DAVID: Database for Annotation, Visualization, and Integrated Discovery.
Glynn Dennis, Brad T Sherman, +4 authors, Richard A Lempicki.
Genome Biol, 2003 May 08; 4(5). PMID: 12734009
Highly Cited.
Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators.
Aihua Zhang, Percy Luk Yeung, +5 authors, J Don Chen.
J Biol Chem, 2004 Jun 09; 279(32). PMID: 15184363
Bioconductor: open software development for computational biology and bioinformatics.
Robert C Gentleman, Vincent J Carey, +22 authors, Jianhua Zhang.
Genome Biol, 2004 Oct 06; 5(10). PMID: 15461798    Free PMC article.
Highly Cited.
Circular binary segmentation for the analysis of array-based DNA copy number data.
Adam B Olshen, E S Venkatraman, Robert Lucito, Michael Wigler.
Biostatistics, 2004 Oct 12; 5(4). PMID: 15475419
Highly Cited.
Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer.
D Flagiello, M Gerbault-Seureau, +3 authors, B Dutrillaux.
Genes Chromosomes Cancer, 1998 Nov 21; 23(4). PMID: 9824202
der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis.
H Tsuda, T Takarabe, T Fukutomi, S Hirohashi.
Genes Chromosomes Cancer, 1999 Jan 19; 24(1). PMID: 9892111
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Erika Krasnickas Keeton, Myles Brown.
Mol Endocrinol, 2005 Apr 02; 19(6). PMID: 15802375
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Common markers of proliferation.
Michael L Whitfield, Lacy K George, Gavin D Grant, Charles M Perou.
Nat Rev Cancer, 2006 Feb 24; 6(2). PMID: 16491069
Highly Cited. Review.
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Jeffrey S Ross, Kai Wang, +12 authors, Philip J Stephens.
Clin Cancer Res, 2013 Apr 12; 19(10). PMID: 23575477
Therapeutic targets in triple negative breast cancer.
Sandra A O'Toole, Jane M Beith, +5 authors, Samantha R Oakes.
J Clin Pathol, 2013 Feb 26; 66(6). PMID: 23436929
Review.
Advances in adjuvant therapy for breast cancer.
Dennis J Slamon, Edward H Romond, Edith A Perez, CME Consultants, Inc.
Clin Adv Hematol Oncol, 2006 Jun 02; 4(3 Suppl 7). PMID: 16736568
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
Novel patterns of genome rearrangement and their association with survival in breast cancer.
James Hicks, Alexander Krasnitz, +20 authors, Anders Zetterberg.
Genome Res, 2006 Dec 05; 16(12). PMID: 17142309    Free PMC article.
Highly Cited.
Are clusters found in one dataset present in another dataset?
Amy V Kapp, Robert Tibshirani.
Biostatistics, 2006 Apr 15; 8(1). PMID: 16613834
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, +21 authors, Joe W Gray.
Cancer Cell, 2006 Dec 13; 10(6). PMID: 17157792
Highly Cited.
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
George W Small, Yue Y Shi, Linda S Higgins, Robert Z Orlowski.
Cancer Res, 2007 May 08; 67(9). PMID: 17483361
Characterization of transcriptional regulatory domains of ankyrin repeat cofactor-1.
Aihua Zhang, Chia-Wei Li, J Don Chen.
Biochem Biophys Res Commun, 2007 May 25; 358(4). PMID: 17521611    Free PMC article.
High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers.
Naoshi Nishida, Takeshi Nagasaka, +2 authors, Ajay Goel.
Cancer Biol Ther, 2007 Apr 26; 6(4). PMID: 17457043
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
Rameen Beroukhim, Gad Getz, +28 authors, William R Sellers.
Proc Natl Acad Sci U S A, 2007 Dec 14; 104(50). PMID: 18077431    Free PMC article.
Highly Cited.
Aurora kinases as anticancer drug targets.
Oliver Gautschi, Jim Heighway, +3 authors, David R Gandara.
Clin Cancer Res, 2008 Mar 19; 14(6). PMID: 18347165
Highly Cited. Review.
The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome.
Andrew R Green, Claire Burney, +7 authors, Eleni Stylianou.
Breast Cancer Res Treat, 2007 Sep 29; 110(3). PMID: 17902051
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Aurora kinase inhibitors--rising stars in cancer therapeutics?
Altaf A Dar, Laura W Goff, +2 authors, Wael El-Rifai.
Mol Cancer Ther, 2010 Feb 04; 9(2). PMID: 20124450    Free PMC article.
Highly Cited. Review.
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.
Hege G Russnes, Hans Kristian Moen Vollan, +20 authors, Anne-Lise Børresen-Dale.
Sci Transl Med, 2010 Jul 02; 2(38). PMID: 20592421    Free PMC article.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Mutual exclusivity analysis identifies oncogenic network modules.
Giovanni Ciriello, Ethan Cerami, Chris Sander, Nikolaus Schultz.
Genome Res, 2011 Sep 13; 22(2). PMID: 21908773    Free PMC article.
Highly Cited.
Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.
Dejan Juric, José Baselga.
J Clin Oncol, 2012 Jan 25; 30(8). PMID: 22271482
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, +12 authors, Nikolaus Schultz.
Cancer Discov, 2012 May 17; 2(5). PMID: 22588877    Free PMC article.
Highly Cited.
The life history of 21 breast cancers.
Serena Nik-Zainal, Peter Van Loo, +47 authors, Breast Cancer Working Group of the International Cancer Genome Consortium.
Cell, 2012 May 23; 149(5). PMID: 22608083    Free PMC article.
Highly Cited.
Mutational processes molding the genomes of 21 breast cancers.
Serena Nik-Zainal, Ludmil B Alexandrov, +51 authors, Breast Cancer Working Group of the International Cancer Genome Consortium.
Cell, 2012 May 23; 149(5). PMID: 22608084    Free PMC article.
Highly Cited.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Matthew J Ellis, Li Ding, +56 authors, Elaine R Mardis.
Nature, 2012 Jun 23; 486(7403). PMID: 22722193    Free PMC article.
Highly Cited.
The landscape of cancer genes and mutational processes in breast cancer.
Philip J Stephens, Patrick S Tarpey, +60 authors, Michael R Stratton.
Nature, 2012 Jun 23; 486(7403). PMID: 22722201    Free PMC article.
Highly Cited.
Sequence analysis of mutations and translocations across breast cancer subtypes.
Shantanu Banerji, Kristian Cibulskis, +44 authors, Matthew Meyerson.
Nature, 2012 Jun 23; 486(7403). PMID: 22722202    Free PMC article.
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
MuSiC: identifying mutational significance in cancer genomes.
Nathan D Dees, Qunyuan Zhang, +9 authors, Li Ding.
Genome Res, 2012 Jul 05; 22(8). PMID: 22759861    Free PMC article.
Highly Cited.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
S Cutrupi, S Reineri, +9 authors, M De Bortoli.
Oncogene, 2012 Jan 18; 31(40). PMID: 22249258
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.
Reina Haque, Syed A Ahmed, +6 authors, Michael F Press.
Cancer Epidemiol Biomarkers Prev, 2012 Sep 20; 21(10). PMID: 22989461    Free PMC article.
The genomic landscape of breast cancer as a therapeutic roadmap.
Matthew J Ellis, Charles M Perou.
Cancer Discov, 2013 Jan 16; 3(1). PMID: 23319768    Free PMC article.
Highly Cited.
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Ron Bose, Shyam M Kavuri, +11 authors, Matthew J Ellis.
Cancer Discov, 2012 Dec 12; 3(2). PMID: 23220880    Free PMC article.
Highly Cited.
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
Aleix Prat, Barbara Adamo, +3 authors, Charles M Perou.
Oncologist, 2013 Feb 14; 18(2). PMID: 23404817    Free PMC article.
Highly Cited. Review.
Racial differences in outcomes of triple-negative breast cancer.
Jose M Pacheco, Feng Gao, +2 authors, Cynthia X Ma.
Breast Cancer Res Treat, 2013 Feb 13; 138(1). PMID: 23400579    Free PMC article.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Balázs Győrffy, Giulia Bottai, +13 authors, Libero Santarpia.
Mol Oncol, 2014 Jan 28; 8(3). PMID: 24462521    Free PMC article.
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast.
Salvatore Piscuoglio, Charlotte K Y Ng, +10 authors, Jorge S Reis-Filho.
Mol Oncol, 2014 Jul 22; 8(8). PMID: 25041824    Free PMC article.
How many etiological subtypes of breast cancer: two, three, four, or more?
William F Anderson, Philip S Rosenberg, +2 authors, Mark E Sherman.
J Natl Cancer Inst, 2014 Aug 15; 106(8). PMID: 25118203    Free PMC article.
Highly Cited. Review.
Cancer progression modeling using static sample data.
Yijun Sun, Jin Yao, Norma J Nowak, Steve Goodison.
Genome Biol, 2014 Aug 27; 15(8). PMID: 25155694    Free PMC article.
Linking signaling pathways to transcriptional programs in breast cancer.
Hatice U Osmanbeyoglu, Raphael Pelossof, Jacqueline F Bromberg, Christina S Leslie.
Genome Res, 2014 Sep 04; 24(11). PMID: 25183703    Free PMC article.
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Madeline M Wong, Chun Guo, Jinsong Zhang.
Am J Clin Exp Urol, 2014 Nov 07; 2(3). PMID: 25374920    Free PMC article.
Review.
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.
Frank B Furnari, Timothy F Cloughesy, Webster K Cavenee, Paul S Mischel.
Nat Rev Cancer, 2015 Apr 10; 15(5). PMID: 25855404    Free PMC article.
Highly Cited. Review.
Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.
Shozo Honda, Phillipe Loher, +5 authors, Yohei Kirino.
Proc Natl Acad Sci U S A, 2015 Jul 01; 112(29). PMID: 26124144    Free PMC article.
Highly Cited.
The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
Heloisa Helena Milioli, Renato Vimieiro, +3 authors, Pablo Moscato.
PLoS One, 2015 Jul 02; 10(7). PMID: 26132585    Free PMC article.
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.
Se Kyung Lee, Soo Youn Bae, +6 authors, Seok Jin Nam.
PLoS One, 2015 Aug 05; 10(8). PMID: 26241661    Free PMC article.
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Giovanni Ciriello, Michael L Gatza, +30 authors, Charles M Perou.
Cell, 2015 Oct 10; 163(2). PMID: 26451490    Free PMC article.
Highly Cited.
Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer.
Chao Liu, Sriganesh Srihari, +5 authors, Kim-Anh Lê Cao.
Mol Oncol, 2015 Oct 13; 10(1). PMID: 26456802    Free PMC article.
FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Yu-Jie Shi, Julia Y S Tsang, +3 authors, Gary M Tse.
Oncotarget, 2015 Dec 18; 7(4). PMID: 26673008    Free PMC article.
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Hyuna Sung, Montserrat Garcia-Closas, +33 authors, Xiaohong R Yang.
Br J Cancer, 2015 Dec 19; 114(3). PMID: 26679376    Free PMC article.
Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis.
Olaia A Martínez-Iglesias, Elvira Alonso-Merino, +12 authors, Ana Aranda.
Proc Natl Acad Sci U S A, 2016 Jan 06; 113(3). PMID: 26729869    Free PMC article.
Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Inna Tishchenko, Heloisa Helena Milioli, Carlos Riveros, Pablo Moscato.
PLoS One, 2016 Jun 25; 11(6). PMID: 27341628    Free PMC article.
COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
Renquan Lu, Xiaobo Hu, +9 authors, Lin Guo.
Nat Commun, 2016 Jul 05; 7. PMID: 27375289    Free PMC article.
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Libero Santarpia, Giulia Bottai, +3 authors, Lajos Pusztai.
Oncologist, 2016 Jul 08; 21(9). PMID: 27384237    Free PMC article.
Review.
Decoding the usefulness of non-coding RNAs as breast cancer markers.
Maria Amorim, Sofia Salta, Rui Henrique, Carmen Jerónimo.
J Transl Med, 2016 Sep 16; 14. PMID: 27629831    Free PMC article.
Review.
The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis.
Olaia Martínez-Iglesias, David Olmeda, +7 authors, Ana Aranda.
Oncotarget, 2016 Nov 03; 7(48). PMID: 27806339    Free PMC article.
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Thomas Fleischer, Jovana Klajic, +15 authors, Vessela N Kristensen.
Oncotarget, 2016 Dec 03; 8(1). PMID: 27911866    Free PMC article.
Computational approach for deriving cancer progression roadmaps from static sample data.
Yijun Sun, Jin Yao, +3 authors, Steve Goodison.
Nucleic Acids Res, 2017 Jan 22; 45(9). PMID: 28108658    Free PMC article.
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Miriam Ragle Aure, Valeria Vitelli, +32 authors, OSBREAC.
Breast Cancer Res, 2017 Mar 31; 19(1). PMID: 28356166    Free PMC article.
Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Wilfred Truin, Rudi M H Roumen, +3 authors, Adri C Voogd.
Breast Cancer Res Treat, 2017 Apr 04; 164(1). PMID: 28365833    Free PMC article.
HNF4A expression as a potential diagnostic tool to discriminate primary gastric cancer from breast cancer metastasis in a Brazilian cohort.
Patrícia Chaves de Freitas Campos Jucá, Stephany Corrêa, +4 authors, Delcio Matos.
Diagn Pathol, 2017 Jun 07; 12(1). PMID: 28583188    Free PMC article.
A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy.
Yu Jin Lim, Sea-Won Lee, +9 authors, In Ah Kim.
Cancer Res Treat, 2017 Dec 09; 50(4). PMID: 29216710    Free PMC article.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
Review.
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.
Marni B Siegel, Xiaping He, +18 authors, Charles M Perou.
J Clin Invest, 2018 Feb 27; 128(4). PMID: 29480819    Free PMC article.
Highly Cited.
Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.
A Mukherjee, R Russell, +9 authors, E Provenzano.
NPJ Breast Cancer, 2018 Mar 14; 4. PMID: 29532008    Free PMC article.
The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
Xin An, Fei Xu, +8 authors, Shusen Wang.
BMC Cancer, 2018 Mar 29; 18(1). PMID: 29587760    Free PMC article.
Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Chitra Joseph, Olivia Macnamara, +10 authors, Abhik Mukherjee.
Br J Cancer, 2018 Mar 29; 118(8). PMID: 29588513    Free PMC article.
TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.
Lindsay A Williams, Ebonee N Butler, +8 authors, Melissa A Troester.
NPJ Breast Cancer, 2018 Jun 29; 4. PMID: 29951581    Free PMC article.
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Mustapha Abubakar, Jonine Figueroa, +8 authors, Paul D Pharoah.
Mod Pathol, 2019 Apr 13; 32(9). PMID: 30976105    Free PMC article.
Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.
Jamie R Kutasovic, Amy E McCart Reed, +16 authors, Peter T Simpson.
J Pathol Clin Res, 2018 Sep 25; 5(1). PMID: 30246500    Free PMC article.
Should a Multigene Signature be Used in all Luminal Early Breast Cancers.
Nawale Hajjaji, Yves Marie Robin, Jacques Bonneterre.
Front Oncol, 2019 Jun 20; 9. PMID: 31214499    Free PMC article.
Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
Mustapha Abubakar, Changyuan Guo, +9 authors, Xiaohong R Yang.
NPJ Breast Cancer, 2019 Aug 03; 5. PMID: 31372496    Free PMC article.
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses.
Pawan Poudel, Gift Nyamundanda, +2 authors, Anguraj Sadanandam.
NPJ Breast Cancer, 2019 Aug 10; 5. PMID: 31396557    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine.
Gift Nyamundanda, Katherine Eason, +2 authors, Anguraj Sadanandam.
Cancers (Basel), 2020 Oct 04; 12(10). PMID: 33007815    Free PMC article.
Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis.
Lara Navarro, Teresa San-Miguel, +6 authors, Concha López-Ginés.
Cells, 2020 Nov 12; 9(11). PMID: 33172155    Free PMC article.
Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Neeraj Kumar, Dan Zhao, +2 authors, Peter H Gann.
BMC Cancer, 2019 Mar 10; 19(1). PMID: 30849944    Free PMC article.
RNA m6A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer.
Lin Yang, Shuangling Wu, +4 authors, Wei-Min Tong.
Front Oncol, 2021 Feb 16; 10. PMID: 33585234    Free PMC article.